Technical Perspectives on Biotech Stocks -- Global Blood Therapeutics, GlycoMimetics, Halozyme Therapeutics, and Idera Pharma

Thursday, March 1, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Mar. 1, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. 

Today we are offering reports on GBT, GLYC, HALO, and IDRA which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com has initiated research coverage on Global Blood Therapeutics Inc. (NASDAQ: GBT), GlycoMimetics
Inc. (NASDAQ: GLYC), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Companies in the Biotech space use live organisms or their products, such as bacteria or enzymes, to manufacture their medicines. They also have more applications than pharmaceutical companies. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Global Blood Therapeutics

Shares in South San Francisco, California headquartered Global Blood Therapeutics Inc. dropped 4.56%, ending Wednesday's trading session at $58.65. The stock recorded a trading volume of 1.15 million shares. The Company's shares have surged 48.48% over the last three months and 110.59% over the past year. The stock is trading 11.42% and 59.67% above its 50-day and 200-day moving averages, respectively. Moreover, shares of the Company have a Relative Strength Index (RSI) of 50.40.  

On February 27th, 2018, Global Blood Therapeutics reported its results for Q4 and year ended December 31st, 2017. For Q4 2017, net loss was $41.3 million; R&D expenses were $31.3 million; and G&A expenses were $10.6 million. For the full year 2017, net loss was $117.0 million; total R&D stock compensation expense incurred was $5.9 million; and total G&A stock compensation expense incurred was $7.8 million.

On February 28th, 2018, research firm Cantor Fitzgerald reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $61 a share to $72 a share. Get the full research report on GBT for free by clicking below at:

www.wallstequities.com/registration/?symbol=GBT

GlycoMimetics

Rockville, Maryland headquartered GlycoMimetics Inc.'s stock declined slightly by 0.65%, closing the day at $23.01 with a total trading volume of 448,298 shares. The Company's shares have advanced 0.88% in the past month, 62.27% in the previous three months, and 276.60% over the past year. The stock is trading 10.41% and 62.59% above its 50-day and 200-day moving averages, respectively. Additionally, shares of GlycoMimetics, which focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the US, have an RSI of 51.80. 

On February 27th, 2018, GlycoMimetics announced that it will host a conference call and webcast on March 06th, 2018, at 8:30 a.m. ET to provide an update on the development plans for GMI-1271 in acute myeloid leukemia, as well as to report the Company's Q4 FY17 and FY17 financial results. A webcast replay of the conference call will be available under the "Investors" tab of the Company's website. Access the free research report on GLYC now by signing up at:

www.wallstequities.com/registration/?symbol=GLYC

Halozyme Therapeutics

On Wednesday, shares in San Diego, California headquartered Halozyme Therapeutics Inc. recorded a trading volume of 1.17 million shares. The stock ended the day 1.21% lower at $19.66. The Company's shares have advanced 1.60% in the past month, 4.91% in the previous three months, and 53.35% over the past year. The stock is trading above its 50-day and 200-day moving averages by 2.49% and 22.27%, respectively. Furthermore, shares of Halozyme Therapeutics have an RSI of 55.87.  

On February 27th, 2018, Halozyme Therapeutics announced that it will be presenting at the Cowen & Company 38th Annual Healthcare Conference on March 13th, 2018, at 9:20 a.m. ET in Boston. Laurie Stelzer, Senior Vice President and CFO, will provide a Company overview. A webcast of the presentation can be accessed under the "Investors" section of the Company's website. Are you already registered with Wall St. Equities? Do so now for free, and get the report on HALO at:

www.wallstequities.com/registration/?symbol=HALO

Idera Pharmaceuticals

Cambridge, Massachusetts-based Idera Pharmaceuticals Inc.'s stock finished yesterday's session flat at $1.77 with a total trading volume of 1.71 million shares. The Company's shares are trading below their 200-day moving average by 10.00%. The stock has an RSI of 37.01.  

On February 19th, 2018, Idera Pharmaceuticals and BioCryst Pharmaceuticals, Inc. announced that they will be presenting at the 2018 Barclays Global Healthcare Conference on March 13th, 2018, at 9:00 a.m. E.T at the Lowes Miami Beach Hotel. As a reminder, on January 22nd, 2018, the duo jointly announced the signing of a definitive merger agreement to combine into a company focused on the development and commercialization of medicines to serve patients suffering from rare diseases. Aspiring Member, please take a moment to register below for your free research report on IDRA at:

www.wallstequities.com/registration/?symbol=IDRA

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----global-blood-therapeutics-glycomimetics-halozyme-therapeutics-and-idera-pharma-300606470.html

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store